- Home
- CWT vs NAMS Comparison
CWT vs NAMS Comparison
Compare CWT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWT | NAMS |
|---|---|---|
| Founded | 1926 | 2019 |
| Country | United States | Netherlands |
| Employees | 1105 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 1997 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CWT | NAMS |
|---|---|---|
| Price | $45.35 | $24.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $53.75 | $50.65 |
| AVG Volume (30 Days) | 383.7K | ★ 1.7M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $963,695,000.00 | $22,503,000.00 |
| Revenue This Year | $9.24 | $29.51 |
| Revenue Next Year | $6.80 | $383.46 |
| P/E Ratio | $45.59 | ★ N/A |
| Revenue Growth | ★ 6.41 | N/A |
| 52 Week Low | $41.29 | $21.02 |
| 52 Week High | $53.82 | $42.21 |
Technical Indicators
Market Signals| Indicator | CWT | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 28.46 | 53.63 |
| Support Level | $44.63 | $21.02 |
| Resistance Level | $45.58 | $26.19 |
| Average True Range (ATR) | 0.80 | 1.23 |
| MACD | -0.16 | 0.45 |
| Stochastic Oscillator | 10.88 | 93.69 |
Price Performance
Historical ComparisonAbout CWT California Water Service Group
California Water Service Group is a U.S. water and utilities holding company based in California. The company provides water utility and other related services in California, Washington, New Mexico, Hawaii and Texas through its wholly-owned subsidiaries. The bulk of the company's business consists of the production, purchase, storage, treatment, testing, distribution, and sale of water for domestic, industrial, public, and irrigation uses, and the provision of water for domestic and municipal fire protection services.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.